Skip to main content
NVDA+0.85%AAPL+0.66%MSFT0.00%GOOGL+1.48%AMZN+1.79%TSM+3.03%SPCX+2.08%AVGO+4.11%META-1.24%TSLA+3.81%LLY+0.18%BRK-B-0.57%MU+3.24%SKHY+2.53%WMT-1.18%AMD+5.42%JPM+0.73%V-0.94%XOM-2.08%JNJ+0.70%ASMLa+2.80%MA-0.82%ABBV-0.06%INTC+3.60%1398.HK+2.15%CVX-1.61%0700.HK-0.31%COST-1.34%CSCO+1.43%KO-0.94%ORCL+4.48%UNH-0.31%PG-0.56%BAC+0.43%1816.HK+1.32%3988.HK+0.66%CAT+2.86%DELL+8.01%HD-0.16%PM+0.56%0857.HK-0.98%0939.HK+0.81%AMAT+2.25%AP2d+2.18%GE+3.18%1288.HK+0.60%LRCX+1.29%0005.HK-5.56%NVS+1.59%MS+2.06%USDJPY+0.64%NZDMXN+0.64%AUDJPY+0.60%EURUSD-0.56%USDMXN+0.55%AUDDKK+0.52%EURAUD-0.51%EURZAR-0.50%EURSEK-0.45%GBPUSD-0.43%GBPTRY+0.41%USDCHF+0.40%NZDJPY+0.39%GBPAUD-0.39%GBPZAR-0.39%CADJPY+0.37%AUDCHF+0.36%EURCNH-0.36%EURNZD-0.33%GBPHKD+0.32%EURHKD-0.32%EURSGD-0.31%USDDKK+0.31%USDCAD+0.29%GBPMXN-0.28%AUDNOK+0.27%EURCAD-0.26%CHFJPY+0.26%EURNOK-0.25%NZDUSD-0.24%SGDJPY+0.24%AUDCAD+0.23%USDPLN+0.22%CHFSEK-0.21%AUDSGD+0.21%GBPSGD-0.21%GBPJPY+0.20%AUDNZD+0.19%GBPNZD-0.18%USDZAR-0.18%NOKJPY+0.18%EURCHF-0.18%USDTRY+0.18%GBPCAD-0.17%USDILS+0.16%NZDCHF+0.16%USDSEK-0.14%EURGBP-0.12%CADCHF+0.11%EURPLN-0.09%EURJPY+0.09%NZDSGD+0.09%CHFSGD-0.07%USDNOK+0.06%EURCZK-0.05%GBPCHF-0.05%AUDUSD-0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%USDTHB-0.03%NZDCAD+0.03%PLNJPY+0.02%CHFNOK-0.01%EURDKK-0.01%USDSGD0.00%HG1+1.90%USOIL-1.54%GAUUSD+1.18%XAUUSD+1.18%COTTON-1.16%UKOIL-1.13%S1-1.07%XAGUSD+0.95%GAGUSD+0.95%C1-0.69%XPTUSD+0.40%W1-0.25%BTCUSD+0.87%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.18%ZECUSDT+6.33%DOGEUSD+20.65%XMRUSDT+0.91%LINKUSD+25.58%BCHUSDT+4.15%XLMUSD+0.35%UNIUSD-0.13%LTCUSD+17.89%SUIUSD+0.91%HBARUSDT-1.56%TONUSD+41.71%TAOUSDT+0.25%AAVEUSD-2.39%DOTUSDT-1.58%ICPUSDT-1.90%ONDOUSDT+0.10%WLDUSDT+0.14%ARBUSDT+0.04%JUPUSDT+0.66%INJUSDT+0.57%ATOMUSDT-1.55%STXUSDT-1.73%TIAUSDT-2.53%FETUSDT+2.84%PYTHUSDT-3.58%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT+0.48%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.16%POLUSDT-0.20%AXSUSDT+0.46%EOSUSDT+0.53%FARTCOINUSDT+1.90%DYDXUSDT+2.19%GALAUSDT+0.41%ORDIUSDT+1.75%RONINUSDT+1.89%NOTUSDT+1.92%NVDA+0.85%AAPL+0.66%MSFT0.00%GOOGL+1.48%AMZN+1.79%TSM+3.03%SPCX+2.08%AVGO+4.11%META-1.24%TSLA+3.81%LLY+0.18%BRK-B-0.57%MU+3.24%SKHY+2.53%WMT-1.18%AMD+5.42%JPM+0.73%V-0.94%XOM-2.08%JNJ+0.70%ASMLa+2.80%MA-0.82%ABBV-0.06%INTC+3.60%1398.HK+2.15%CVX-1.61%0700.HK-0.31%COST-1.34%CSCO+1.43%KO-0.94%ORCL+4.48%UNH-0.31%PG-0.56%BAC+0.43%1816.HK+1.32%3988.HK+0.66%CAT+2.86%DELL+8.01%HD-0.16%PM+0.56%0857.HK-0.98%0939.HK+0.81%AMAT+2.25%AP2d+2.18%GE+3.18%1288.HK+0.60%LRCX+1.29%0005.HK-5.56%NVS+1.59%MS+2.06%USDJPY+0.64%NZDMXN+0.64%AUDJPY+0.60%EURUSD-0.56%USDMXN+0.55%AUDDKK+0.52%EURAUD-0.51%EURZAR-0.50%EURSEK-0.45%GBPUSD-0.43%GBPTRY+0.41%USDCHF+0.40%NZDJPY+0.39%GBPAUD-0.39%GBPZAR-0.39%CADJPY+0.37%AUDCHF+0.36%EURCNH-0.36%EURNZD-0.33%GBPHKD+0.32%EURHKD-0.32%EURSGD-0.31%USDDKK+0.31%USDCAD+0.29%GBPMXN-0.28%AUDNOK+0.27%EURCAD-0.26%CHFJPY+0.26%EURNOK-0.25%NZDUSD-0.24%SGDJPY+0.24%AUDCAD+0.23%USDPLN+0.22%CHFSEK-0.21%AUDSGD+0.21%GBPSGD-0.21%GBPJPY+0.20%AUDNZD+0.19%GBPNZD-0.18%USDZAR-0.18%NOKJPY+0.18%EURCHF-0.18%USDTRY+0.18%GBPCAD-0.17%USDILS+0.16%NZDCHF+0.16%USDSEK-0.14%EURGBP-0.12%CADCHF+0.11%EURPLN-0.09%EURJPY+0.09%NZDSGD+0.09%CHFSGD-0.07%USDNOK+0.06%EURCZK-0.05%GBPCHF-0.05%AUDUSD-0.05%USDCNH-0.05%USDCOP-0.04%USDHKD+0.04%USDTHB-0.03%NZDCAD+0.03%PLNJPY+0.02%CHFNOK-0.01%EURDKK-0.01%USDSGD0.00%HG1+1.90%USOIL-1.54%GAUUSD+1.18%XAUUSD+1.18%COTTON-1.16%UKOIL-1.13%S1-1.07%XAGUSD+0.95%GAGUSD+0.95%C1-0.69%XPTUSD+0.40%W1-0.25%BTCUSD+0.87%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.18%ZECUSDT+6.33%DOGEUSD+20.65%XMRUSDT+0.91%LINKUSD+25.58%BCHUSDT+4.15%XLMUSD+0.35%UNIUSD-0.13%LTCUSD+17.89%SUIUSD+0.91%HBARUSDT-1.56%TONUSD+41.71%TAOUSDT+0.25%AAVEUSD-2.39%DOTUSDT-1.58%ICPUSDT-1.90%ONDOUSDT+0.10%WLDUSDT+0.14%ARBUSDT+0.04%JUPUSDT+0.66%INJUSDT+0.57%ATOMUSDT-1.55%STXUSDT-1.73%TIAUSDT-2.53%FETUSDT+2.84%PYTHUSDT-3.58%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT+0.48%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.16%POLUSDT-0.20%AXSUSDT+0.46%EOSUSDT+0.53%FARTCOINUSDT+1.90%DYDXUSDT+2.19%GALAUSDT+0.41%ORDIUSDT+1.75%RONINUSDT+1.89%NOTUSDT+1.92%
VP

Vertex Pharmaceuticals Incorporated (VX1d)

FRA • Healthcare

€461.7
-€8.3 (-1.8%)
Market closed

October 27, 2026 at 16:30 UTC

Open€464.7
Day Range€458.8 - €464.7
Avg. Volume (3M)35
Market Cap€116.2B
P/E Ratio26.7
52 Week Range
€351.6€480.4

Interactive Chart

17:42:00 UTC

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned€3.3B100%
Gross Profitminus cost of goods€2.8B85%
Operating Incomeminus R&D and overhead€1.2B38%
Net Incomeminus taxes and the rest€1.1B33%

In plain terms: out of every €100 in revenue, Vertex Pharmaceuticals Incorporated keeps €33 as net profit.

Fundamentals & Financials

Revenue (TTM)
€12.6B
Net Income (TTM)
€4.4B
EPS (TTM)
€17.31
ROA (TTM)
16.06%
Current Ratio
3.19
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

€1.96Q4 2019
€2.1Q1 2020
€2.82Q2 2020

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q2 2020

Vertex Pharmaceuticals’ revenue rose 12.6% to about $3.3 billion in the second fiscal quarter of 2026, reported Aug. 3 and based on preliminary results, while adjusted EPS of $4.14 came in line with the $4.15 estimate, -0.2%, and was up 7.8% from $3.84 a year ago. Net income increased 6.6% to about $1.1 billion from about $1.0 billion a year ago, operating income came to about $1.3 billion, gross margin was near 86%, and operating margin was around 38%. Operating cash flow came to about $1.1 billion, the company repurchased about $474 million of stock, and consensus for the next period calls for EPS of $4.16.

Next report — what to expect

Vertex Pharmaceuticals (VX1.DE) reports next on November 2, 2026. Wall Street consensus calls for EPS of $4.20 on revenue of $3.01 billion. For trailing context, revenue grew +12.6% year over year last quarter. The company has beaten EPS in 4 of its 8 most recent quarters, so attention may center on upside versus those estimates.

View full earnings history

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated trades on XETRA as VX1.DE and operates in biotechnology, developing and commercializing medicines centered on cystic fibrosis. In FY2025, the company generated $12.1 billion in revenue. Its marketed portfolio is led by CFTR modulators that treat defined cystic fibrosis mutation groups, and the company was founded in 1989 in Boston, Massachusetts.

Name
Vertex Pharmaceuticals Incorporated
CEO
Reshma Kewalramani
Website
www.vrtx.com
Industry
Healthcare
Year Founded
1989
Employees
6,400

Today's Snapshot

AI-generated

The day ended with VX1d 2.4% lower at 458.80, while its sector was flat. Volume was about a sixth of its usual level.

Trading Volume

Below 10d avg (29)

3

vs S&P 500 Today

Underperforming Market

-2.74%

Updated: October 27, 2026 at 15:08 UTC

VX1d Headlines

Vertex to buy Crinetics for $10 billion

July 6, 2026

3 min read

Biotech ETFs Flash Classic Reversal Signal

April 1, 2026

2 min read

Executives File New SEC Form 144 Sales

February 27, 2026

4 min read
View All News

Technical Indicators

5 Buy2 Neutral1 Sell
VX1d is showing a constructive bias as price sits near the short-term averages while remaining well above the 200-day level, signaling longer-term bullish placement; momentum indicators such as a positive MACD and a rising momentum reading support that bias, and on-balance volume is positive, suggesting buying pressure. However, trend strength is muted with a low ADX, and the pivot sits above the current price, which may act as overhead resistance while volatility is moderate. Technical takeaway: Buy — momentum and volume favor the upside, but the trend lacks strong conviction.
All signals
  • EMA (5 indicators)$419.89 - $460.88
    Buy
  • RSI (14)51.15
    Neutral
  • Stochastic %K (14, 3, 3)70.02
    Neutral
  • MACD Level (12, 26)3.25
    Buy

Peers & Related Assets

ALNYAlnylam Pharmaceuticals, Inc.
$227.66+1.6%
BBIOBridgeBio Pharma, Inc.
$68.15-0.6%
BMRNBioMarin Pharmaceutical Inc.
$55.75-0.4%
IONSIonis Pharmaceuticals, Inc.
$43.42+1.1%
PTCTPTC Therapeutics, Inc.
$61.07+0.8%
CRSPCRISPR Therapeutics AG
$49.01-0.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.